Cover Image

Patient preferences for treatment of advanced melanoma: impact of comorbidities

Background and objectives Choice of treatment for advanced melanoma is crucially influenced by comorbidities and patient preferences. Our study aimed to investigate the impact of comorbidities on preferences. Patients and methods 150 patients with melanoma stage IIC-IV completed a discrete choice ex...

Full description

Saved in:
Bibliographic Details
Main Authors: Weilandt, Juliane (Author) , Diehl, Katharina (Author) , Schaarschmidt, Marthe-Lisa (Author) , Kiecker, Felix (Author) , Sasama, Bianca (Author) , Pronk, Melanie (Author) , Ohletz, Jan (Author) , Könnecke, Andreas (Author) , Müller, Verena (Author) , Utikal, Jochen (Author) , Hillen, Uwe (Author) , Harth, Wolfgang (Author) , Ludwig-Peitsch, Wiebke (Author)
Format: Article (Journal)
Language:English
Published: 2021
In: Journal der Deutschen Dermatologischen Gesellschaft
Year: 2021, Volume: 19, Issue: 1, Pages: 58-70
ISSN:1610-0387
DOI:https://doi.org/10.1111/ddg.14293
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/https://doi.org/10.1111/ddg.14293
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ddg.14293
Get full text
Author Notes:Juliane Weilandt, Katharina Diehl, Marthe-Lisa Schaarschmidt, Felix Kiecker, Bianca Sasama, Melanie Pronk, Jan Ohletz, Andreas Könnecke, Verena Müller, Jochen Utikal, Uwe Hillen, Wolfgang Harth, Wiebke K. Peitsch
Description
Summary:Background and objectives Choice of treatment for advanced melanoma is crucially influenced by comorbidities and patient preferences. Our study aimed to investigate the impact of comorbidities on preferences. Patients and methods 150 patients with melanoma stage IIC-IV completed a discrete choice experiment to determine preferences for outcome (overall response rate [ORR], 2-year survival, progression-free survival [PFS], time to response [TTR], kind of adverse events [AE], AE-related treatment discontinuation) and process attributes (frequency and route of administration [RoA], frequency of consultations) of systemic melanoma treatments. The impact of comorbidities was assessed by analysis of variance and multivariate regression. Results Participants with hypertension and other cardiovascular diseases attached significantly greater importance to TTR and RoA than others. Respondents with arthropathy cared more about TTR (β = 0.179, P = 0.047) and RoA, but less about ORR (β = -0.209, P = 0.021). Individuals with diabetes considered AE (β = 0.185, P = 0.039) and frequency of consultations more essential, but ORR less relevant. Those with other malignancies were particularly worried about treatment discontinuation (β = 0.219, P = 0.008), but less about ORR (β = -0.202, P = 0.015). Participants with depression focused more on PFS (β = 0.201, P = 0.025) and less on TTR (β = -0.201, P = 0.023) and RoA (β = -0.167, P = 0.050). Conclusions Treatment preferences of melanoma patients vary significantly dependent on comorbidities.
Item Description:First published: 04 October 2020
Gesehen am 13.04.2021
Physical Description:Online Resource
ISSN:1610-0387
DOI:https://doi.org/10.1111/ddg.14293

Similar Items